Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Backed by 8VC.
About the role
The Associate Director/Director, Clinical Development Program Management is a senior leadership role responsible for driving the strategic and operational execution of one or more clinical development programs from early- through late-stage trials. This individual will serve as a central point of accountability for cross-functional program delivery, a primary partner for Core Team and workstream Program Owners for Lyell’s asset(s). Found on 1752vc Careers, the job board for startup and VC roles.
What they're looking for
- Associate Director - Director - Demonstrated experience leading and managing cross-functional strategic and tactical teams in a matrixed environment, with strong accountability for team performance and delivery
- Deep understanding of the end-to-end drug development process, GCP/ICH guidelines, and clinical trial operations
- Experience contributing to regulatory submissions supporting marketing approval (BLA/NDA/MAA), including submission planning, readiness tracking, and cross-functional coordination
- Experience in cell therapy, immuno-oncology, or oncology drug development
More about this role
Using living cells to treat – and sometimes even cure – cancer is one of the most dramatic advances in modern medicine. Patients with hematologic malignancies have been successfully treated with cell therapies. However, these profound results have not yet been achieved in patients with solid tumors, representing approximately 90% of all cancers. And for patients with hematologic malignancies, there is a need for next-generation cell therapies that can deliver increased response rates and longer duration of response. We are a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies. Lyell’s product candidates are enhanced with novel technology designed to generate T cells that resist exhaustion and have qualities of durable stemness in order to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical response. We were founded by cell therapy pioneers whose decades of research elevated the broader understanding of T-cell biology and its interaction with cancer. In our quest to advance next-generation CAR T-cell therapies, we have built a fully integrated company capable of...
Browse similar: Startup jobs · San Francisco Bay Area